Anticipated Financials in Boston Scientific's Upcoming Quarterly Financial Statement
Boston Scientific Corporation (BSX), a global leader in the development, manufacturing, and marketing of medical devices, is gearing up to announce its fiscal Q2 2025 earnings results on July 23, 2025. The company, based in Marlborough, Massachusetts, has been on an upward trajectory, surpassing Wall Street's bottom-line estimates in the past four quarters.
Analysts forecast an adjusted EPS of $0.72 for the quarter, marking a 16.1% increase from $0.62 in the same quarter the previous year. This growth trend is expected to continue for the full fiscal year 2025, with analysts predicting adjusted EPS to be around $2.91 to $2.94, representing an approximately 15.9-16.0% increase from $2.51 in fiscal 2024.
In terms of revenue, Q2 2025 is anticipated to bring in about $4.66 billion, up approximately 20.9% year-over-year. The company's net income for the quarter is expected to be $672 million, a 36.3% increase compared to the prior year’s quarter.
Shares of BSX have performed exceptionally well over the past year, with a 37.1% increase, outperforming the S&P 500’s 13.4% rise in the same period. This bullish sentiment is reflected in analyst ratings, with 27 analysts recommending a "Strong Buy," two having a "Moderate Buy" rating, and one giving a "Hold" rating.
The upcoming earnings report will provide more definitive insights, but current expectations point to solid growth and positive analyst sentiment for Boston Scientific in 2025. The company's diversified medical device portfolio and strategic acquisitions are key drivers of this optimism.
BSX operates through key segments including Cardiovascular, Rhythm and Neuro, and MedSurg. The company has reassured investors that it expects to bolster its U.S. manufacturing capacity, and it plans to absorb a potential $200 million tariff impact through higher sales and discretionary spending cuts.
As of writing, BSX is trading below the average analyst price target of $120.50. With a market cap of $154.3 billion, Boston Scientific Corporation (BSX) continues to be a significant player in the medical devices industry.
Disclaimer: This article's information and data are solely for informational purposes. For more detailed information, view the website Disclosure Policy here. Sohini Mondal did not have positions in any of the securities mentioned in this article.
The upcoming fiscal Q2 2025 earnings results of Boston Scientific Corporation (BSX) could reveal further growth in the company, with analysts predicting an adjusted EPS of $0.72, marking an increase of 16.1% year-over-year. The company is also expected to generate $4.66 billion in revenue during Q2 2025, representing a 20.9% year-over-year growth. These financial projections demonstrate the positive sentiments and optimistic outlook towards BSX in the medical devices industry.
